Update shared on 02 Dec 2025
Fair value Increased 0.17%Analysts have raised their price target for Life Healthcare Group Holdings slightly, increasing it from R13.76 to R13.78. This adjustment is based on improved expectations for revenue growth and profit margins.
What's in the News
- The Board approved a final gross cash dividend of 35.0 cents per ordinary share, to be paid from income reserves and subject to a 20% South African dividend withholding tax. Trading ex-dividend begins on 17 December 2025, with the payment date set for 22 December 2025. (Key Developments)
- Earnings guidance for the fiscal year ended 30 September 2025 has been provided. Expected normalized earnings per share from continuing operations are between 97.5 cents and 102.0 cents. Other performance metrics are also outlined for both continuing and discontinued operations. (Key Developments)
Valuation Changes
- Consensus Analyst Price Target: Increased slightly from ZAR 13.76 to ZAR 13.78.
- Discount Rate: Remained unchanged at 16.73%.
- Revenue Growth: Increased significantly from 2.08% to 6.14%.
- Net Profit Margin: Improved from 10.90% to 14.63%.
- Future P/E: Decreased notably from 10.17x to 6.92x.
Have other thoughts on Life Healthcare Group Holdings?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.